|
Jan 4
|
Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
|
|
Dec 20
|
Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
|
|
Nov 17
|
Dermata (DRMA) Up on FDA Nod to Begin Pivotal Study of Acne Drug
|
|
Nov 16
|
Dermata Announces Exercise of Warrants for $2.26 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
|
|
Nov 16
|
Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols
|
|
Aug 10
|
Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
|